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Abstract Tumor hypoxia, or low oxygen concentration, is a
result of disordered vasculature that lead to distinctive hypoxic
microenvironments not found in normal tissues. Many tradi-
tional anti-cancer agents are not able to penetrate into these
hypoxic zones, whereas, conventional cancer therapies that
work by blocking cell division are not effective to treat tumors
within hypoxic zones. Under these circumstances the use of
magnetic nanoparticles as a drug delivering agent system under
the influence of external magnetic field has received much
attention, based on their simplicity, ease of preparation, and
ability to tailor their properties for specific biological applica-
tions. Hence in this review article we have reviewed current
magnetic drug delivery systems, along with their application
and clinical status in the field of magnetic drug delivery.
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Introduction
Hypoxia is a pathological condition in which the whole
body or specific tissues are deprived of an adequate oxygen
supply. This mismatch between oxygen supply and its
demand at the cellular level can be due to various reasons
such as cardiac arrest, strangulation, high intake of carbon
monoxide, exercise, or reduced vasculature as seen in
tumor cells (Brahimi-Horn et al. 2007). Of various types of
hypoxia discussed above, tumor hypoxia is one of the most
important pathological conditions for tumor therapy and
diagnosis. In general, a tumor environment is characterized
by a highly proliferating mass of cells that grows faster
than the vasculature creating an avascular environment
deficient in oxygen (Brahimi-Horn et al. 2007). Such
hypoxic zones have been postulated to have a reduced
response to radiotherapy due to a decrease in oxygen free
radicals that are required to produce enough DNA damage
result in cell death (Moeller et al. 2007). In addition, cells
of these regions are considered to be chemotherapy-resis-
tant due to limited delivery of drugs via the circulation
(Brahimi-Horn et al. 2007). In such cases, the delivery of
nanoparticles or drug loaded nanoparticles via angiogene-
sis is also not much effective due to the formation of neo-
vessels which are often distorted and irregular and thus less
efficient in oxygen, nutrient transport and drug delivery.
This lack of efficient transport system in the body to deliver
drug to the tumor cells has recently attracted lot of con-
sideration and lot of delivery vehicles has been postulated.
Of which magnetic nanoparticles as a drug delivery system
has received considerable attention.
Magnetic drug delivery system works on the delivery of
magnetic nanoparticles loaded with drug to the tumor site
under the influence of external magnetic field (Fig. 1).
However, development of this delivery system mandates
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that the nanoparticles behave magnetic only under the
influence of external magnetic field and are rendered
inactive once the external magnetic field is removed. For-
tunately, such magnetic properties are usually acquired by
very small nanoparticles within the size range of less than
10 nm, due to the presence of single domain state. In
contrast, large magnetic particles are well known for their
multidomain structure. These multidomain states are sep-
arated by domain walls, as depicted in Fig. 2. This for-
mation of the domain walls is energetically favorable if the
energy consumption for the formation of the domain walls
is lower than the formation of single domain states (Gubin
2009). As the dimensions of the particles are reduced, it
costs more energy to create a domain wall than to support a
single-domain state. Thus below a critical size all the
domain walls are washed away and the particle becomes a
single domain particle (Lu et al. 2007). In practice, as the
particle size is reduced, the coercivity increases to a
maximum and then decreases toward zero. Below a critical
diameter the coercivity becomes zero. Such particles are
termed superparamagnetic (Fig. 3) (Jun et al. 2007). Here
coercivity is defined as the force applied to reduce the
residual magnetic field left in the magnetic particles to zero
after the removal of an external magnetic field (Fig. 4).
Therefore, when the particle size is small the spin-flip
barrier for the reversal of the magnetic moments is very
small, and the energy at the room temperature for small
particles is enough for simple magnetization reversal
energy i.e. Ms2V * kBT * 25 meV at room temperature
(Gubin 2009; Krishnan 2010). Thus when typical ferro-
magnets obtain a critical diameter of about 5–10 nm it
paves the way to become superparamagnetic nanoparticle.
The superparamagnetism of any magnetic nanomaterial is
basically caused by thermal effects where the thermal
fluctuations are strong enough to spontaneously demagne-
tize a previously saturated assembly; therefore these par-
ticles have zero coercivity and have no hysteresis
(Krishnan 2010). As a result, superparamagnetic nanopar-
ticles become magnetic in the presence of an external
magnet, but revert to a nonmagnetic state when the external
magnet is removed. This avoids an ‘active’ behavior of the
particles when there is no applied field. This behavior of
superparamagnetic materials results in potential advantages
to deliver therapeutics onto specific sites under the influ-
ence of external magnetic field and can be reverted to their
nonmagnetic states by removing external magnetic field to
allow them to be excreted (Park et al. 2010).
Ferrite oxide—magnetite (Fe3O4) is the naturally
occurring minerals on earth which is widely used in the
form of superparamagnetic nanoparticles for diverse bio-
logical applications, such as MRI, magnetic separation, and
magnetic drug delivery. However, the use of magnetic
nanoparticles in vivo needs lot of surface modification so
as to protect them from reticuloendothelial system and
increase the stability of molecule in vivo. Organic ligands
such as polyethylene glycol, dextran, aminosilanes are
commonly used to stabilize the magnetic nanoparticles
(Laurent et al. 2008; Reddy et al. 2012). Unfortunately,
these surface protectants modulate the magnetic properties
by modifying the anisotropy and decreasing the surface
magnetic moment of the metal atoms located at the surface
of the particles (Paulus et al. 1999; van Leeuwen et al.
1994). This reduction has been mainly associated to the
existence of a magnetically dead layer on the surface of
particles (Kodama 1999). Thus the effect of size and sur-
face coating of magnetic nanoparticles are both very
important for the fabrication of nanomaterials for their role
Fig. 1 Schematic representation of Magnetic drug delivery system
under the influence of external magnetic field. Fmag is direction of
external magnetic field are targeted. Copyrighted from reference
(Park et al. 2010)
Fig. 2 Magnetic moment in both ferromagnetic and superparamag-
netic materials. On application of the magnetic field the domain walls
in ferromagnetic materials are washed away and aligned to the
direction of the magnetic field. Whereas, in a superparamagnetic
materials usually defined as the single domain structure has no
domain walls, but magnetic moments align to the direction of the
applied external magnetic field. The domain structure of the magnetic
materials has been drawn for simplicity. Copyrighted from reference
(Mody et al. 2013)
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as diagnostic and therapeutic agents (Liu et al. 2011; Pal-
iwal et al. 2010). Any change in size and surface coating
will modulate the magnetic properties such as Coercivity
(Hc) of these nanospheres of the nanoparticles and hence
can vary the effectiveness of these diagnostic as well as
therapeutic agents. It is imperative to mention that the
design of novel MNPs for biomedical application requires
careful evaluation of the effect of surface modification,
size, shape on its magnetic properties. A thorough con-
sideration of each design parameter must be evaluated to
produce MNPs that can overcome biological barriers and
carry out its function. Additional information on the effect
of change in shape, size, and surface coating of nanopar-
ticles on its magnetic properties is beyond the scope of this
review and readers are requested to refer book titled
‘‘Magnetic Nanoparticles’’ by Dr. Sergey P. Gubin and a
review by Krishnan (Gubin 2009; Krishnan 2010). In
particular, it must be concluded that the magnetic response
of a nanoparticle to an inert coating is rather complex and
system specific; the effect of coating cannot be predeter-
mined before the actual magnetic measurements have been
performed. Even with limited information on the behavior
of these systems various attempts have been made to bio-
engineer magnetic nanoparticles so as to utilize them for
magnetic drug delivery. In the following section, we have
tried to outline few of these applications followed by their
current status in clinical trials.
Magnetic nanoparticles for drug delivery
Magnetic nanoparticles offer the possibility of being sys-
tematically administered but directed towards a specific
target in the human body while remaining ultimately
localized, by means of an applied magnetic field. Even
though the concept of using magnetic particles for drug
delivery was proposed as far back as 1970, the field of
magnetic drug delivery has only recently received much
attention (Senyei et al. 1978; Widder et al. 1978). Usually
Fig. 3 Schematic illustration of the coercivity–size relations of small
particles. Copyrighted from reference (Jun et al. 2007)
Fig. 4 A typical hysteresis loop
such as that obtained from
superparamagnetic and
ferromagnetic materials. Figure
modified and copyrighted from
reference (Mody et al. 2013)
Appl Nanosci (2014) 4:385–392 387
123
therapeutic agents are attached to the surface of magnetic
nanoparticles or encapsulated within a nanocomposite
mixture of a polymer and magnetic nanoparticle. In this
case they can be operated under the influence of very low
values of applied magnetic field. Ideal properties for the
nanocomplexes which are to be used must be those with
high values of magnetization at the operational tempera-
ture. Magnetic particles from iron, cobalt, and nickel are
favorable in such situations due to their specific magnetic
properties but the control of the particle size and shape, and
the matrix or medium in which the particle is embedded is
also critical. More commonly, these particles may have
magnetic cores with an external coating of a polymer or
other metals and nonmetals such as gold or silica. They can
also be nanocomposite mixtures consisting of magnetic
nanoparticles encapsulated within a porous polymer.
Presence of the polymers or various metal/nonmetal coat-
ing provides an opportunity to anchor various therapeutic
drugs or DNA for targeted gene delivery (McBain et al.
2008b). Another approach lies in encapsulating a cytotoxic
drug along with magnetic nanospheres inside the polymer
matrix. Once targeted to the site of action, the sustained
delivery of the drug molecule at the site of action will
provide its therapeutic effect.
Once the therapeutic moiety has been loaded on to the
nanoparticles and placed in vivo these magnetic nano-
complexes are often directed on a target site using high-
field rare earth magnets. The presence of high gradient field
which is focused over a specific site onto the body forces
and captures the particles at the targeted tissue. Although
this may be an effective strategy for targets close to the
body’s surface the effect wears off for applications deep
within the body as the magnetic field strength falls off
rapidly with distance and inner sites become more difficult
to target. Some groups have recently proposed to circum-
vent this problem by implanting magnets in the body near
the target site (Kubo et al. 2000; Yellen et al. 2005). Ide-
ally, the magnetic particles should not retain any remnant
magnetization once the magnetizing field has been
removed. This avoids aggregation of the magnetic nano-
particles due to dipolar interactions between their respec-
tive magnetizations and facilitates their excretion from the
body.
An optimum magnetic response has been achieved using
magnetic ferrofluids and the most common coating or
encapsulating materials for in vivo applications are poly-
saccharides like dextran, and polymers such as polyethyl-
ene glycol and polyacrylamide. Recently carbon coating
has been used as biocompatible material. One of the
advantages of using carbon is its high capacity of adsorp-
tion. Chen et al. developed a magnetic drug delivery sys-
tem in which doxorubicin (DOX) was chemically bonded
to Fe3O4 nanoparticles (Chen et al. 2010). This complex
was then embedded in a polyethylene glycol (PEG) func-
tionalized porous silica shell (Fe3O4-DOX/pSiO2-PEG)
(Fig. 5). The presence of a porous silica shell is not only
provided a protective layer for drug molecules and mag-
netite nanoparticles, but also created a thin barrier for the
DOX release from the carrier. Hence this composite
magnetic drug delivering system exhibited a slower of
DOX than seen in DOX-conjugated Fe3O4 nanoparticles
alone (Fig. 6). In addition, biocompatible polymer PEG,
allowed this complex to escape reticuloendothelial system,
thus allowing drugs to be administered over prolonged
periods of time.
Magnetic nanoparticles can also be of enormous
potential for the diagnosis and therapy of brain tumors.
One of the most common ways to target nanoparticles
across blood brain barrier (BBB) is via enhanced per-
meation and retention effect (EPR). However, EPR can be
limited by environment of the tumor, such as hypovas-
cularity, fibrosis, or necrosis even when pathologic pro-
cesses compromise the integrity or function of the BBB
(Kreuter 2001; Lockman et al. 2002; Pardridge 2002).
Towards this end, Liu et al. developed MNPs of iron
oxide (Fe3O4) by encapsulating them within the polymer
poly[aniline-co–N-(1-one-butyric acid)] aniline (SPAnH)
(Liu et al. 2010). The anticancer agent epirubicin was
immobilized on the surface of these MNPs. This novel
magnetic drug delivery system was targeted to the brain
using focused ultrasound and magnetic targeting as a
synergistic delivery system. Both ultrasound and an
externally applied magnetic field actively increased the
local MNP concentration. The results demonstrated that
the control animals showed no MNP accumulation in the
tumor region even 6 h after MNP administration. How-
ever, on application of external magnet, approximately
15-fold higher than the therapeutic range of epirubicin per
gram of tissue were taken up by tumor cells. The confocal
and fluorescence microscopy and Prussian blue staining
further confirmed the presence of more epirubicin-MNPs
at the tumor site than in the contralateral side (Liu et al.
2010).
Similarly, Chertok et al. also successfully delivered
polyethyleneimine (PEI)-modified magnetic nanoparticles
(GPEI) with a magnetic saturation of 93 emu/g Fe to brain
tumors. The results in vitro showed high cell association
and low cellular toxicity. However, initial investigation
conducted in vivo in the absence of the magnetic field did
not successfully accumulate magnetic nanoparticles onto
tumors of rats harboring orthotopic 9L-gliosarcomas, due
to poor pharmacokinetic properties (Chertok et al. 2010).
However, intra-carotid administration in conjunction with
magnetic targeting resulted in 30-fold (p = 0.002) increase
in tumor entrapment of GPEI compared to that seen with
intravenous administration (Fig. 7). Figure 7 shows the
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MRI head scans of 9L glioma bearing rats. This figure
clearly indicates the presence of iron oxide nanoparticles in
the tumor lesion (Chertok et al. 2010).
Fig. 5 Synthetic Scheme for
the development of Doxorubicin
loaded magnetic drug delivery
system. Copyrighted from
reference (Chen et al. 2010)
Fig. 6 Comparative release profile of Doxorubicin in iron oxide
conjugated DOX. Iron oxide conjugated dox in silica and PEG
protected shell. Copyrighted from reference (Chen et al. 2010)
Fig. 7 Representative subsets of axial MRI head-scans of 9L-glioma
bearing rats before (baseline) intravenous administration of a G100 or
b GPEI and after magnetic targeting (post-targ). Figure copyrighted
from reference (Chertok et al. 2010)
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Ito et al. were the first to target esophageal cancer in
rabbits by oral administration under the influence of a
magnetic field in 1990 (Ito et al. 1990). The first clinical
cancer therapy trials in humans using magnetic micro-
spheres (MMS) was reported in Germany in 1996 and
involved treatment of advanced solid liver cancer in 14
patients (Lu¨bbe et al. 1996). These MMS had a diameter of
approximately 100 nm and were filled with 4-epidoxo-
rubcin. The results clearly showed that the MMS accu-
mulated in the target area and were nontoxic. Similarly,
Arias et al. investigated the capabilities of polycyanoac-
rylate nanospheres with a magnetite core as delivery sys-
tems for the antitumor drug 5-flurouracil (Arias et al.
2008). By loading this hydrophilic drug onto a carrier
system the therapeutic efficacy improved, while its unde-
sired toxic effects were reduced. The choice of the biode-
gradable polymeric shell, namely polyalkylcyanoacrylates,
was based on well-demonstrated therapeutic results in the
treatment of both resistant and nonresistant cancers of a
wide range of cell lines, and the low toxicity levels seen in
Phase I and II clinical trials (Merle et al. 2006). In addition
to this application, magnetic microspheres loaded with the
c-emitting radioisotope 90Y have also been successfully
used for a radionuclide therapy in the eradication of small
subcutaneous B-lymphoma in mouse (Ha¨feli et al. 1997).
Bacterial magnetosomes (BMs) synthesized by mag-
netotactic bacteria have also been used as carriers for
enzymes, nucleic acids and antibodies (Balkwill et al.
1980; Ota et al. 2003; Matsunaga et al. 2003). Their
application as targeted drug carriers has been commended
due to their unique features, such as paramagnetism,
nanoscale, narrow size distribution and membrane-bound
form (Gru¨nberg et al. 2004).
Magnetic nanoparticles for gene delivery
One of the promising applications of MNPs is their
application to deliver therapeutics at local inflammatory
process of the musculoskeletal system in humans. At
present, many of the local inflammatory conditions which
are currently treated with systemic nonsteroidal anti-
inflammatory drugs are hampered by systemic side effects
(Za´visˇova´ et al. 2007). Hence, MNPs could serve a major
purpose in drug delivery to inflammatory sites when
directed by external magnetic field, thus reducing systemic
side effects. Other studies have also shown the advantages
of directing the magnetic drug delivering vehicle to the
lungs, which can be done with a properly designed mag-
netic targeting system (Gonda 2000). Numerous attempts
have been made to use immunotoxins for targeted treat-
ment of malignant lung diseases (Ally et al. 2005). Finally,
these novel formulations have been shown to increase the
drug accumulation in the stratum corneum and epidermis
plus dermis, which clearly demonstrates the potential of
MNPs for topical application (Lacava et al. 2002; Primo
et al. 2007).
Magnetic nanoparticle technology also offers the
potential to achieve selective and efficient delivery of
therapeutic genes by using external magnetic fields. As
compared to traditional gene delivery strategies, magnetic
drug delivery system has been shown to significantly
increase gene delivery to human xenograft tumors models.
This implies that they therefore have potential to turn the
challenge of gene therapy in vivo into a new frontier for
cancer treatment (Li et al. 2012). Mah et al. were the first to
demonstrate that the conjugation to microspheres results in
a higher effective concentration of vector to target cells as
it moves through the tissue vasculature. In fact, both
in vitro and in vivo studies demonstrated that microsphere-
mediated delivery of rAAV vector results in higher trans-
duction efficiencies than delivery of free vector alone,
when administered either intramuscularly or intravenously
(Mah et al. 2002). Currently, in vitro magnetofection kits
utilizing cationic polymer coated MNPs are commercially
available (Mykhaylyk et al. 2007; Pan et al. 2007; Ryther
et al. 2005; Schillinger et al. 2005). Huth et al. showed that
the cationic polymeric gene carriers, such as polyethylen-
imine (PEI) increase the cellular uptake of magnetofectins
(Huth et al. 2004). This increased uptake is shown to
proceed by endocytosis with an increased rate of internal-
ization under the influence of magnetic field. Similarly,
McBain and Coworkers showed that an MNP-gene based
system focused to the target site/cells via high-field/high-
gradient magnets has been shown to be efficient and rapid
for in vitro transfection. This MNP-gene based system
compares well with cationic lipid-based reagents, produc-
ing good overall transfection levels with lower doses and
shorter transfection times (McBain et al. 2008b). Their
experimental results indicate that the system significantly
enhances overall in vitro transfection levels in human air-
way epithelial cells, compared to both static field tech-
niques (p \ 0.005) and the cationic lipids (p \ 0.001).
To date, gene delivery via magnetic particles is pre-
dominantly used to reduce the time needed for transfection
or minimize the dose of vector. Work is also being con-
ducted on improving the overall transfection efficiency of
this technique by using dynamic magnetic fields produced
from oscillating arrays of permanent rare earth magnets
(McBain et al. 2008). The preliminary data from these
studies suggests that this approach can improve the level of
transfection [tenfold compared to static magnetic fields.
This can be due to the extra energy inducted into the sys-
tem, which improves particle uptake (McBain et al. 2008).
However, targeting siRNA to specific tissues still has not
lived up to its potential clinical application, and much more
390 Appl Nanosci (2014) 4:385–392
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work is needed via collaboration with bioengineers and
scientists across various scientific disciplines (Sun et al.
2008).
Conclusion
The use of magnetic nanoparticles as a drug delivering
system is still defined by its biocompatibility and selective
targeting to the desired cell or tissue under the guidance of
external magnetic field. Advances in current technologies
and the development of magnetic nanoparticles as drug
delivery systems to deliver drugs to tumor hypoxic zones
have fast-tracked in the past decade and led to the devel-
opment of various magnetic nano-formulations such as
liposomes, metallic/nonmetallic, and polymeric nanoparti-
cles. These novel drug delivery systems has increased the
ability to deliver drugs for which conventional therapy has
shown limited efficacy (Sun et al. 2008). This technology
will not only minimize invasive procedures, but also reduce
side effects to healthy tissues, which are two primary
concerns in conventional cancer therapies (Sun et al. 2008;
Veiseh et al. 2010). The field of magnetic drug delivery is
still at infancy, and synthesis of better magnetic drug
delivery system and integration of multifunctional ligands
are being continuously investigated so as to carry it from
the bench-top to the clinic (Wahajuddin 2012). Until then
the concerns about their elimination and long term toxicity
remain barriers to clinical entry.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Ally J, Martin B, Behrad Khamesee M, Roa W, Amirfazli A (2005)
Magnetic targeting of aerosol particles for cancer therapy.
J Magn Magn Mater 293:442–449
Arias JL, Gallardo V, Ruiz MA, Delgado A´V (2008) Magnetite/poly
(alkylcyanoacrylate) (core/shell) nanoparticles as 5-Fluorouracil
delivery systems for active targeting. Eur J Pharm Biopharm
69:54–63
Balkwill DL, Maratea D, Blakemore RP (1980) Ultrastructure of a
magnetotactic spirillum. J Bacteriol 141:1399–1408
Brahimi-Horn MC, Chiche J, Pouysse´gur J (2007) Hypoxia and
cancer. J Mol Med 85:1301–1307
Chen F-H, Zhang L-M, Chen Q-T, Zhang Y, Zhang Z-J (2010)
Synthesis of a novel magnetic drug delivery system composed of
doxorubicin-conjugated Fe3O4 nanoparticle cores and a PEG-
functionalized porous silica shell. Chem Commun 46:8633–8635
Chertok B, David AE, Yang VC (2010) Polyethyleneimine-modified
iron oxide nanoparticles for brain tumor drug delivery using
magnetic targeting and intra-carotid administration. Biomaterials
31:6317–6324
Gonda I (2000) The ascent of pulmonary drug delivery. J Pharm Sci
89:940–945
Gru¨nberg K, Mu¨ller E-C, Otto A, Reszka R, Linder D, Kube M,
Reinhardt R, Schu¨ler D (2004) Biochemical and proteomic
analysis of the magnetosome membrane in magnetospirillum
gryphiswaldense. Appl Environ Microbiol 70:1040–1050
Gubin SP (ed) (2009) Magnetic nanoparticles. Wiley-VCH Verlag
GmbH and Co, KGaA
Ha¨feli U, Schu¨tt W, Teller J, Zborowski M (eds) (1997) Scientific and
clinical applications of magnetic carriers. Plenum Publishing
Corp, NY, USA
Huth S, Lausier J, Gersting SW, Rudolph C, Plank C, Welsch U,
Rosenecker J (2004) Insights into the mechanism of magneto-
fection using PEI-based magnetofectins for gene transfer. J Gene
Med 6:923–936
Ito R, Machida Y, Sannan T, Nagai T (1990) Magnetic granules: a
novel system for specific drug delivery to esophageal mucosa in
oral administration. Int J Pharm 61:109–117
Jun Y.-w, Choi J.-s, Cheon J (2007) Heterostructured magnetic
nanoparticles: their versatility and high performance capabilities,
chemical communications, pp 1203–1214
Kodama RH (1999) Magnetic nanoparticles. J Magn Magn Mater
200:359–372
Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs.
Adv Drug Deliv Rev 47:65–81
Krishnan KM (2010) Biomedical nanomagnetics: a spin through
possibilities in imaging diagnostics, and therapy. IEEE Trans
Magn 46:2523–2558
Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T (2000)
Targeted delivery of anticancer drugs with intravenously
administered magnetic liposomes in osteosarcoma-bearing ham-
sters. Int J Oncol 17:309–315
Lacava LM, Lacava ZGM, Azevedo RB, Chaves SB, Garcia VAP,
Silva O, Pelegrini F, Buske N, Gansau C, Da Silva MF, Morais
PC (2002) Use of magnetic resonance to study biodistribution of
dextran-coated magnetic fluid intravenously administered in
mice. J Magn Magn Mater 252:367–369
Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller
RN (2008) Magnetic iron oxide nanoparticles: synthesis stabil-
ization, vectorization, physicochemical characterizations, and
biological applications. Chem Rev 108:2064–2110
Li C, Li L, Keate AC (2012) Targeting cancer gene therapy with
magnetic nanoparticles. Oncotarget 3:365–370
Liu H-L, Hua M-Y, Yang H-W, Huang C-Y, Chu P-C, Wu J-S, Tseng
I-C, Wang J–J, Yen T-C, Chen P-Y, Wei K-C (2010) Magnetic
resonance monitoring of focused ultrasound/magnetic nanopar-
ticle targeting delivery of therapeutic agents to the brain. Proc
Natl Acad Sci 107:15205–15210
Liu F, Laurent S, Fattahi H, Elst LV, Muller RN (2011) Superpara-
magnetic nanosystems based on iron oxide nanoparticles for
biomedical imaging. Nanomedicine 6:519–528
Lockman PR, Mumper RJ, Khan MA, Allen DD (2002) Nanoparticle
technology for drug delivery across the blood-brain barrier. Drug
Dev Ind Pharm 28:1–13
Lu A-H, Salabas EL, Schu¨th F (2007) Magnetic nanoparticles:
synthesis protection, functionalization, and application. Angew
chem int ed 46:1222–1244
Lu¨bbe AS, Bergemann C, Riess H, Schriever F, Reichardt P,
Possinger K, Matthias M, Do¨rken B, Herrmann F, Gu¨rtler R,
Hohenberger P, Haas N, Sohr R, Sander B, Lemke A-J,
Ohlendorf D, Huhnt W, Huhn D (1996) Clinical experiences
with magnetic drug targeting: a phase I study with 40-epidoxo-
rubicin in 14 patients with advanced solid tumors. Cancer Res
56:4686–4693
Mah C, Fraites JTJ, Zolotukhin I, Song S, Flotte TR, Dobson J,
Batich C, Byrne BJ (2002) Improved method of recombinant
AAV2 delivery for systemic targeted gene therapy. Mol Ther
6:106–112
Appl Nanosci (2014) 4:385–392 391
123
Matsunaga T, Ueki F, Obata K, Tajima H, Tanaka T, Takeyama H,
Goda Y, Fujimoto S (2003) Fully automated immunoassay
system of endocrine disrupting chemicals using monoclonal
antibodies chemically conjugated to bacterial magnetic particles.
Anal Chim Acta 475:75–83
McBain SC, Griesenbach U, Xenariou S, Keramane A, Batich CD,
Alton EWFW, Dobson J (2008a) Magnetic nanoparticles as gene
delivery agents: enhanced transfection in the presence of
oscillating magnet arrays. Nanotechnology 19:405102
McBain SC, Yiu HH, Dobson J (2008b) Magnetic nanoparticles for
gene and drug delivery. Int J Nanomedicine 3:169–180
Merle P, Si Ahmed S, Habersetzer F, Abergel A, Taieb J, Bonyhay L,
Costantini D, Dufour-Lamartinie J, Tre´po C (2006) P. 384 Phase
1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-
transdrug (DT) for patients with advanced hepatocellular
carcinoma (HCC). J Clin Virol 36(2):179
Mody V, Singh A, Bevins W (2013) Basics of magnetic nanoparticles
for their application in the field of magnetic fluid hyperthermia.
Eur J Nanomed (accepted)
Moeller B, Richardson R, Dewhirst M (2007) Hypoxia and
radiotherapy: opportunities for improved outcomes in cancer
treatment. Cancer Metastasis Rev 26:241–248
Mykhaylyk O, Vlaskou D, Tresilwised N, Pithayanukul P, Mo¨ller W,
Plank C (2007) Magnetic nanoparticle formulations for DNA
and siRNA delivery. J Magn Magn Mater 311:275–281
Ota H, Takeyama H, Nakayama H, Katoh T, Matsunaga T (2003)
SNP detection in transforming growth factor-b1 gene using
bacterial magnetic particles. Biosens Bioelectron 18:683–687
Paliwal SR, Paliwal R, Mishra N, Mehta A, Vyas SP (2010) A novel
cancer targeting approach based on estrone anchored stealth
liposome for site-specific breast cancer therapy. Curr Cancer
Drug Targets 10:343–353
Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, Li Q, Xu P, Huang T
(2007) Dendrimer-modified magnetic nanoparticles enhance
efficiency of gene delivery system. Cancer Res 67:8156–8163
Pardridge WM (2002) Drug and gene delivery to the brain: the
vascular route. Neuron 36:555–558
Park JH, Saravanakumar G, Kim K, Kwon IC (2010) Targeted
delivery of low molecular drugs using chitosan and its deriva-
tives. Adv Drug Deliv Rev 62:28–41
Paulus PM, Bo¨nnemann H, van der Kraan AM, Luis F, Sinzig J, de
Jongh LJ (1999) Magnetic properties of nanosized transition
metal colloids: the influence of noble metal coating. Eur Phys J
D-Atomic, Mol, Opt Plasma Phys 9:501–504
Primo FL, Michieleto L, Rodrigues MAM, Macaroff PP, Morais PC,
Lacava ZGM, Bentley MVLB, Tedesco AC (2007) Magnetic
nanoemulsions as drug delivery system for Foscan: skin
permeation and retention in vitro assays for topical application
in photodynamic therapy (PDT) of skin cancer. J Magn Magn
Mater 311:354–357
Reddy LH, Arias JL, Nicolas J, Couvreur P (2012) Magnetic
nanoparticles: design and characterization, toxicity and biocom-
patibility, pharmaceutical and biomedical applications. Chem
Rev 112:5818–5878
Ryther RCC, Flynt AS, Phillips Iii JA, Patton JG (2005) siRNA
therapeutics: big potential from small RNAs. Gene Therapy
12:5–11
Schillinger U, Brill T, Rudolph C, Huth S, Gersting S, Kro¨tz F,
Hirschberger J, Bergemann C, Plank C (2005) Advances in
magnetofection—magnetically guided nucleic acid delivery.
J Magn Magn Mater 293:501–508
Senyei A, Widder K, Czerlinski G (1978) Magnetic guidance of drug-
carrying microspheres. J Appl Phys 49:3578–3583
Sun C, Lee JSH, Zhang M (2008) Magnetic nanoparticles in MR
imaging and drug delivery. Adv Drug Deliv Rev 60:1252–1265
van Leeuwen DA, van Ruitenbeek JM, de Jongh LJ, Ceriotti A,
Pacchioni G, Ha¨berlen OD, Ro¨sch N (1994) Quenching of
magnetic moments by ligand-metal interactions in nanosized
magnetic metal clusters. Phys Rev Lett 73:1432–1435
Veiseh O, Gunn JW, Zhang M (2010) Design and fabrication of
magnetic nanoparticles for targeted drug delivery and imaging.
Adv Drug Deliv Rev 62:284–304
Wahajuddin SA (2012) Superparamagnetic iron oxide nanoparticles:
magnetic nanoplatforms as drug carriers. Int J Nanomedicine
7:3445–3471
Widder KJ, Senyel AE, Scarpelli GD (1978) Magnetic microspheres:
a model system of site specific drug delivery in vivo. Proc Soc
Exp Biol Med 158:141–146
Yellen BB, Forbes ZG, Halverson DS, Fridman G, Barbee KA,
Chorny M, Levy R, Friedman G (2005) Targeted drug delivery
to magnetic implants for therapeutic applications. J Magn Magn
Mater 293:647–654
Za´visˇova´ V, Koneracka´ M, Sˇtrba´k O, Tomasˇovicˇova´ N, Kopcˇansky´ P,
Timko M, Vavra I (2007) Encapsulation of indomethacin in
magnetic biodegradable polymer nanoparticles. J Magn Magn
Mater 311:379–382
392 Appl Nanosci (2014) 4:385–392
123
